SCHEMBL5855090

SCHEMBL5855090

OCC(CO)CCCCCl

nearest known ligand 0.46

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
ALDH1A1 P00352 3/20 0.40
TSHR P16473 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20609096 0.97 LMNA (0.50) LMNAALDH1A1TSHRTDP1
SCHEMBL5855477 0.97 LMNA (0.50) LMNAALDH1A1TSHRTDP1
SCHEMBL5857074 0.91
SCHEMBL13130048 0.77 ALDH1A1 (0.50) LMNAALDH1A1TSHR
SCHEMBL3706416 0.77 LMNA (0.46) LMNAALDH1A1TSHRTDP1TP53
SCHEMBL11357667 0.76
SCHEMBL39091 0.75 LMNA (0.50) LMNAALDH1A1TSHR
SCHEMBL2512604 0.74
SCHEMBL23340667 0.74 ALDH1A1 (0.62) LMNAALDH1A1TSHRTDP1TP53
SCHEMBL272442 0.73 LMNA (0.55) LMNAALDH1A1TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12504558-B2 Semiconductor-nanoparticle-ligand complex, preparation method therefor, photosensitive resin composition, optical film, electroluminescent diode and electronic device DUK SAN NEOLUX CO., LTD. (KR) 2025-12-23 US disclosed
US-20240008304-A1 SEMICONDUCTOR-NANOPARTICLE-LIGAND COMPLEX, PREPARATION METHOD THEREFOR, PHOTOSENSITIVE RESIN COMPOSITION, OPTICAL FILM, ELECTROLUMINESCENT DIODE AND ELECTRONIC DEVICE DUK SAN NEOLUX CO., LTD. (KR) 2024-01-04 US disclosed
CN-116490559-A Semiconductor nanoparticle-ligand complex, method for preparing same, photosensitive resin composition, optical film, electroluminescent diode, and electronic device 德山新勒克斯有限公司 2023-07-25 CN disclosed
WO-2022108350-A1 SEMICONDUCTOR-NANOPARTICLE-LIGAND COMPLEX, PREPARATION METHOD THEREFOR, PHOTOSENSITIVE RESIN COMPOSITION, OPTICAL FILM, ELECTROLUMINESCENT DIODE AND ELECTRONIC DEVICE 덕산네오룩스 주식회사 2022-05-27 WO disclosed
US-20070027198-A1 Crystal of heterocyclic compound OKADAI TAKESHI 2007-02-01 US disclosed
US-20070027198-A1 Crystal of heterocyclic compound OKADAI TAKESHI 2007-02-01 US disclosed
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 US disclosed
CN-1238347-C Heterocyclic derivatives NIPPON SHINYAKU CO LTD (JP) 2006-01-25 CN disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US disclosed
CN-1430612-A Hete rocyclic derivatives NIPPON SHINYAKU CO LTD (JP) 2003-07-16 CN disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB LMNA 606/4885ALDH1A1 760/4885TSHR 1666/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE LMNA 601/4885ALDH1A1 571/4885TSHR 2487/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC LMNA 636/4885ALDH1A1 557/4885TSHR 2672/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC LMNA 636/4885ALDH1A1 557/4885TSHR 2672/4885
US-20070027198-A1 Crystal of heterocyclic compound GPR119, ACACA, HMGCR LMNA 1457/4885ALDH1A1 2064/4885TSHR 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.